Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature

Antibiotics (Basel). 2023 Aug 17;12(8):1328. doi: 10.3390/antibiotics12081328.

Abstract

Bone and joint infections (BJIs) caused by multidrug-resistant gram-negative bacteria are becoming a concern due to limited therapeutic options. Although not approved for these indications, an ever-growing amount of evidence supports the efficacy and safety of ceftazidime-avibactam as a therapy for osteomyelitis and prosthetic joint infections. Here, we present three cases of difficult-to-treat resistant Pseudomonas aeruginosa osteomyelitis that were successfully treated with ceftazidime-avibactam alone or in combination therapy with fosfomycin and amikacin. Ceftazidime-avibactam was prescribed at a daily dose of 2.5 g every 8 h for 42 days in all cases. One potential drug-related adverse effect was observed, i.e., Clostridioides difficile infection, which occurred after fourteen days of treatment with ceftazidime-avibactam.

Keywords: Pseudomonas aeruginosa; arthritis; ceftazidime–avibactam; osteomyelitis.

Publication types

  • Case Reports

Grants and funding

The publication costs of this article were covered by the Fund for VQR improvement assigned to the Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties of the University of Palermo.